GPR56/ADGRG1 is associated with response to antidepressant treatment
It is not fully understood why some patients respond or do not respond to antidepressant treatment. Here the authors show that in the blood of individuals with depression, GPR56 expression increases in responders to antidepressant treatment, but not in non-responders.
Guardado en:
Autores principales: | Raoul Belzeaux, Victor Gorgievski, Laura M. Fiori, Juan Pablo Lopez, Julien Grenier, Rixing Lin, Corina Nagy, El Chérif Ibrahim, Eduardo Gascon, Philippe Courtet, Stéphane Richard-Devantoy, Marcelo Berlim, Eduardo Chachamovich, Jean-François Théroux, Sylvie Dumas, Bruno Giros, Susan Rotzinger, Claudio N. Soares, Jane A. Foster, Naguib Mechawar, Gregory G. Tall, Eleni T. Tzavara, Sidney H. Kennedy, Gustavo Turecki |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3469c4a94a4c4f539ae3e87d5f59f012 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of GPR56/ADGRG1 in health and disease
por: Abhishek Kumar Singh, et al.
Publicado: (2021) -
Conserved residues in the extracellular loop 2 regulate Stachel-mediated activation of ADGRG2
por: Abanoub A. Gad, et al.
Publicado: (2021) -
Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer
por: Song Wu, et al.
Publicado: (2019) -
Orphan GPR61, GPR62 and GPR135 receptors and the melatonin MT2 receptor reciprocally modulate their signaling functions
por: Atsuro Oishi, et al.
Publicado: (2017) -
The polymicrogyria-associated GPR56 promoter preferentially drives gene expression in developing GABAergic neurons in common marmosets
por: Ayako Y. Murayama, et al.
Publicado: (2020)